Become a Member

What’s Happening on the Alzheimer’s/Dementia Front?

Doc Gumshoe checks in on the Gray Plague

By Michael Jorrin, "Doc Gumshoe", November 14, 2017

[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, he chooses his own topics and his words and opinions are his alone]

I don’t know about you folks out there in Gumshoe Nation, but I get the strong feeling that most people don’t want to talk about Alzheimer’s disease (AD).   It just looms over us.   We have seen people who have succumbed to AD, and the picture is not pretty.  And there is a general sense that medical science doesn’t have a whole lot of ammunition on hand to combat it.   But never fear, Doc Gumshoe is not going to devote this piece to reiterating the disappointing news items about Alzheimer’s.   Instead, I’m trying to accentuate the positive and latch on to the affirmative, but  without totally eliminating the negative.

The generally gloomy view is at least in part a result of a widespread expectation that there should be “miracle cures” for all manner of diseases and conditions.   The absence of such a cure is equivalent to failure.   We hear that medical science and Big Pharma have utterly failed in their quest to find a cure for cancer.   If the only indication of success were a “miracle cure,” a drug or treatment that stopped every form of cancer and resulted in decades of totally disease-free survival for all patients, then, indeed, all efforts have resulted in failure.   But as I have repeatedly stated in these pieces, remission rates for many cancers, including the most common cancers, have improved significantly, and many millions of people, here and elsewhere, are enjoying symptom-free lives due to these many non-miraculous treatment modalities.   I do not consider that a failure.

But negative news keeps trickling out.   For example, it was announced a few days ago that Novartis, Amgen, and the Banner Alzheimer’s Institute are going to work together on a program aimed at preventing AD by means of a drug in a class called BACE inhibitors, which I discussed in a previous post about AD, back on December 21, 2015.   BACE 1 (beta-site amyloid precursor protein cleaving enzyme 1) is thought to lead to the formation of beta amyloid in the brain, which in turn is thought to lead to the cognitive disability that characterizes Alzheimer’s.   Therefore, inhibition of this enzyme should prevent or delay the symptoms of AD.   However, previous trials of BACE inhibitors have not been successful, and the news of this collaboration was generally met with a distinct lack of enthusiasm.   In fact, even before any results were announced, failure was anticipated.

This kind of response gets around and shapes people’s views.   Quite naturally, lots of us are concerned about the possibility that we will develop Alzheimer’s disease.   Any time we forget anything, we think, is that the dreaded Alzheimer’s plague getting ready to strike?   A few days ago, for no reason whatever, I was trying to remember the name of the woman who sang “Monotonous” in the show “New Faces of 1952.”   It was of no importance, of course.   I was hardly going to cheat by resorting to Google.   I tried to put it out of my mind, but it kept nibbling at me.   I could hear the song in my head – “I met a Rajah, amusing fool, when on my way to Istanbul, bought me the Black Sea for a swimming pool.”    After a couple of days of intermittent itching, her name popped into my head – Eartha Kitt!   Excellent!   I am not slipping into Alzheimer’s, at least, not yet.

Then along came a piece of genuinely good news.   Persons who experience occasional memory lapses or blanks and are aware of their episodes of forgetfulness are not any more likely to develop dementia than the rest of the population.   The behavior that is much more likely to be a precursor of dementia is forgetfulness that the person is not aware of.   They go about their lives happily unaware of what they have forgotten.   The blanks in their minds do not cause them any distress.   I remember that for years I had to struggle to remember the word “refractory,” and had to recollect it by thinking of surfaces – those that absorb light, those that are transparent, those that reflect, and – aha! – those that refract!   That certainly troubled me.   Was I slipping into dementia?   Would I have to poke and prod at the contents of my noggin to bring to mind the words I needed?   But apparently that type of forgetfulness affects great numbers of people who do not go on to develop dementia.   The mechanism of ordinary forgetfulness is similar to minor traffic nuisances in the network of neurons.   The destination is there, but the street is temporarily obstructed because the school in the middle of the block is having a street fair.   One has to find another route, as I did with “refractory.”

Obstructions in the neuronal pathways leading to “Eartha Kitt” or “refractory” do not come close to what happens in Alzheimer’s, which is more like an epic snowstorm that clogs all the roads and streets and eventually – over years – renders them impassable.   The person with Alzheimer’s is unable to recall simple everyday words – the wife of a good friend would forget the word “floor” and helplessly point downward to try to indicate what she was talking about.   And the avenues that convey the signals that tell us to eat and breathe also become obstructed by this blizzard in our brains, with fatal results.   The brain blizzard that blocks the way to simple words eventually also clogs other brain functions – no mail deliveries, no ambulances or fire trucks, no food deliveries to the grocery store.

Some possibly good news about Alzheimer’s

The discouraging statistic that has rocketed about the news media is that an overwhelming proportion of all the proposed drugs to treat Alzheimer’s disease fail in the clinical trial stage.   The usual headline is “99.5 % of Alzheimer’s drugs fail!”   So, in that context, what good news could there possibly be?

An organization called “ResearchersAgainstAlzheimer’s” has a more hopeful perspective.   Here’s their “Statement of Beliefs:”

“We have heard some say that Alzheimer’s disease is an inevitable part of aging. Others have claimed that it simply cannot be prevented or effectively treated anytime soon. Still others believe that we simply cannot afford to do what it would take to stop the disease. They are all wrong.

As men and women of science, we are united by a simple but bold belief: It is possible to prevent and effectively treat Alzheimer’s disease within our lifetimes, but only if our nation does what is necessary:

  1. Set an aggressive goal of stopping Alzheimer’s disease by 2025, because it will focus the energies of the research community;
  2. Invest significant resources in Alzheimer’s disease research and innovation, because our commitment to cures must match the scale of the challenge;
  3. Institute reforms to accelerate the drug pipeline and deliver therapies to patients faster, because the ultimate goal of research is to bring help to those afflicted, and to prevent the disease from afflicting future generations.

If government, private industry, and the research community unite with a common goal and purpose backed with the necessary leadership, resources and incentives, the power of scientific research can be unleashed to unlock new possibilities, to deliver new cures – and to prevent and treat Alzheimer’s disease.”

Their website lists 17 founding members from prestigious institutions, including  Johns Hopkins, Rush, Cleveland Clinic, Washington University in St Louis, Indiana University, Baylor, University of Tokyo, Oxford, Mayo Clinic, Harvard Medical School, University of Pennsylvania, University of Southern California, University of California San Francisco.   So let’s grant them a degree of legitimacy.

And what they have most recently announced is an unexpected surge in the number of new AD drugs.   For example, there are now 58 drugs in Phase 2 clinical trials, and 32 in Phase 3 clinical trials.   Two of these are projected to get FDA approval in 2018.   These are masitinib, which is the main product of AB Sciences in Paris, and brexpiprazole (Rexulti), from Otsuka Pharmaceuticals and Lundberg.   Masitinib is a tyrosine kinase inhibitor, and it targets the formation of tau protein in the brain, which is one of the two postulated causes of AD.   Brexpiprazole is a dopamine receptor agonist.   It is a successor to aripiprazole (Abilify), which is widely used in mental illnesses such as schizophrenia, but also to address behavioral issues stemming from depression.   The expectation for brexpiprazole is that it will help to manage behavioral symptoms such as aggression in AD.

Other drugs, such as TRx0237, from TauRX Therapeutics, and Belsomra, from Merck, both of which have been discussed in previous Doc Gumshoe sermons about AD, are expected to launch in 2018.   The projected launch dates for those 32 drugs in Phase 3 trials extend to 2025.

As for the 58 drugs now in Phase 2, the projected launch dates for almost all of these begin in 2022 and go all the way to 2028.   Some of these drugs are already approved for other diseases and conditions, and the trials in these drugs are to learn if they might have some kind of beneficial effect on AD.   Overall, the drugs target a comprehensive range of the putative pathophysiologies of AD.

For the 32 drugs now in Phase 3 trials, the targets are as follows:

Amyloid plaque 13 drugs (45% of total)
Neurotransmission   11 drugs (34%)
Insulin/glucose     2 drugs (6%)
Tau protein         2 drugs (6%)
Other               4 drugs (13%)

And for the 58 drugs in Phase 2:

Amyloid plaque      10 drugs (17% of total)
Neurotransmission   17 drugs (29%)
Insulin/glucose     4 drugs (7%)
Blood/vascular      3 drugs (5%)
Tau protein         7 drugs (12%)
Inflammation        2 drugs (3%)
Neuronal/
synaptic growth     5 drugs (8%)
Other               10 drugs (17%)

What sticks out for me is a certain shift in focus – more interest in tau protein and less in amyloid plaque, but also new areas of interest, such as inflammation (a hugely popular topic these days) and also the growth of neurons and the synapses that link them.   Although some of the drugs being investigated would aim to do no more than alleviate some of the symptoms, a respectable proportion of the research is directed at the root causes of AD.

The whole enterprise – a total of 90 drugs either in Phase 2 or Phase 3 – represents a colossal economic wager, as well as a huge outpouring of hope.   This does not happen without a considerable underpinning of optimism.   The pharmaceutical companies backing those 90 drugs include just about every outfit I’ve ever heard of, as well as many that I’ve never come across.   The outlook is entirely contrary to the gloomy picture painted by sweeping statements about the failures of clinical trials in AD.

In my opinion, this does not so much hold out promise of a single “magic bullet” that will cure or reverse AD, removing it forever as a subject of concern.   Instead, what it looks like is the confident expectation that a range of approaches will essentially render AD much more manageable.   Some of the mechanisms may indeed slow the deposition of the amyloid plaque or the neurofibrillary tangles which are now thought to be the underlying pathologies of AD.   Others may encourage the formation of more new neuronal pathways in our brains, so that despite the blizzard, some avenues continue to be open.   This happens all the time anyway; that’s how we form new memories and new associations.   But perhaps that function can be assisted.

Are you getting our free Daily Update
"reveal" emails? If not,
just click here...


All in all, the optimistic projection is not that a nuclear device can accurately target and obliterate the capital of Alzheimer’s, but that a concerted campaign from air, land, and sea, will defeat this formidable foe.   Or, for a different simile, a really powerful and effective armada of snowplows to keep the streets and roads clear.

Can Alzheimer’s disease and dementia be prevented?

The answer, at least according to an enormously ambitious paper published in Lancet this past July, seems to be “yes,” at least to some degree (Livingston G.   Lancet 2017 DOI: http://dx.doi.org/10.1016/S0140-6736(17)31363-6).   A couple of years ago, Lancet formed a group to address dementia, initially called the Dementia Care Commission, but now renamed the Dementia Prevention, Intervention, and Care Commission.   The work of that group is reported in that Lancet paper, which runs almost two hundred pages.   I’m not going into it in any great detail right now, but let me just put a few of the premises and findings in perspective.

An important point of departure is that Alzheimer’s is not synonymous with dementia.   The type of dementia associated with AD is different from other types of dementia, as in dementia resulting from trauma or a cerebrovascular incident.   The physiologic features of AD do not automatically result in dementia in every case.   Those AD features include the notorious amyloid beta and tau protein, and also Lewy bodies in the brain, which are mostly associated with Parkinson’s disease.  Persons with these elements in their brain frequently demonstrate characteristics of dementia, but not invariably.   In a previous Doc Gumshoe piece about AD, I described a famous study in nuns, which found a strong link between the language they used in the essays they wrote when they first entered the nunnery and the likelihood of becoming demented in their later years.   The analysis was not highly sophisticated.   It simply measured the length of words and sentences.   The nuns whose essays, composed for the most part when they were in their early twenties, employed longer words and sentences, were for the most part less likely to present symptoms of dementia fifty or sixty years later.   The nuns in this study had also given permission to have their brains examined on autopsy, and it was found that many nuns who had many of the physiologic features of dementia in their brains, finished their lives in a totally lucid state.

The Lancet paper identified a number of what they termed “Population Attributable Factors” (PAFs) which they thought were responsible for as much as 35% of the incidence of dementia.   The study was based in part on observation of about 10,000 adults in the UK.

An important concept, not only in the Lancet paper, but in other investigations of the incidence of dementia, is the concept of cognitive reserve.   This sounds fairly obvious – if you have more reserve of any faculty, including cognition, you can afford to spare more of that faculty than a person that has less of it to start out with.   And the data seem to support this concept.   For example, several factors may affect cognitive reserve, either positively or negatively.   Early life education and later life cognitive training boost cognitive reserve, while peripheral hearing loss diminishes cognitive reserve because of the lack of stimulating input that persons with hearing loss experience.

The Lancet paper separates those modifiable risk factors according to periods in an individual’s life.    In early life, poor education (i.e., no schooling beyond 11th grade) may account for 8% of dementia incidence, while in the middle years, the principal PAFs are hearing loss (9%), hypertension (2%) and obesity (1%), and in late life the PAFs are smoking (5%), depression (4%), physical inactivity (3%), social isolation (2%), and diabetes (1%).   It’s highly likely that a number of those risk factors overlap; for example, high-school dropouts are far more likely to be smokers than are college graduates, and hypertension, obesity, physical inactivity, and diabetes certainly do tend to go together.   Other data, by the way, tend to corroborate the Lancet conclusions, e.g., a 19% increase in midlife obesity in China was accompanied by a similar increase in the incidence of dementia.   Cause and effect?   Coincidence?

One of the authors of the paper, Lon Schneider of USC, commented that the findings of the Lancet Commission partly contradict the conclusion of an NIH committee in 2010 that pronounced that there were no measures to prevent AD.   He acknowledged that it would not be possible to confirm these findings through controlled studies – it would hardly be ethical to assign one cohort in a randomized trial to smoke cigarettes and the other cohort to abstain, so that 50 years later the incidence of AD in the two cohorts could be compared.   But the data strongly support the concept of prevention as a way of reducing dementia risk.

The Lancet paper places the factors into three main sets, as shown in the diagram: one set includes the factors that affect cognitive reserve; a second set includes factors that affect brain inflammation; and a third set includes factors that contribute to cerebrovascular damage.   There is overlap between the sets, and the single factor that affects all three sets is exercise.

pastedGraphic.png

Can we reduce the risk of dementia/Alzheimer’s disease by dietary changes? 

You will have noticed that one of the factors thought to reduce the development of dementia is adherence to the Mediterranean diet, which is widely thought to be beneficial in the management of diabetes, hypertension, and elevated cholesterol.   There have been several studies attempting to find a relationship between dietary intake and the incidence of Alzheimer’s disease.   What can be said of these studies in general is that they did indeed find relationships between what we eat and the brain changes that are thought to lead to AD; however, their findings don’t amount to a complete formula for an AD- or dementia-protective diet.

Perhaps the strongest evidence relates to some antioxidant nutrients, including in particular vitamin E and vitamin C, which have been shown, at least in animal studies, to protect the brain from damage due to inflammatory and oxidative mechanisms.   Three prospective human studies assessed the relationship between those nutrients and the risk of Alzheimer’s disease – one in Chicago, one in Rotterdam, and one in New York City.   The Chicago and Rotterdam studies found a significantly lower risk of AD in individuals with a higher intake of vitamin E; the New York study did not find that association, but it happened that the vitamin E intake in subjects in the New York study was very much lower than in the Chicago or Rotterdam cohorts, so that may have accounted for the difference.   The relationship between vitamin C intake and AD was much less robust than with vitamin E; only the Rotterdam study found a link.

It needs to be emphasized that none of those studies found a link between vitamin E and vitamin C supplements and a reduced risk of Alzheimer’s.   To the extent that a reduced risk was detected in relationship with vitamin E intake, it was only as a result of the presence in the diet of foods that were rich in vitamin E.   A possible reason for the absence of beneficial effect with vitamin E supplements is that those supplements usually consist only of alpha-tocopherol; however, gamma-tocopherol is more abundant in the diet, and it has been suggested that the combined intake of all eight forms of tocopherol reduce oxidative stress and inflammation more than alpha-tocopherol alone.   We are told that the foods richest in vitamin E are vegetable oils, nuts (especially almonds), seeds, and also whole grains, eggs, and some fruits and vegetable such as avocados, apples, and melons.

Dietary fats, especially transfats, may significantly increase the risk of Alzheimer’s, but the evidence concerning fats in general is somewhat contradictory.   It’s intuitively attractive that cholesterol in the vascular system in the brain cannot be good for cognition, and a study in Japan showed a strong relationship between cholesterol levels and the deposition of amyloid plaques in the brain.   The study followed 147 adults for up to 15 years before their deaths, and then performed autopsies on their brains.   Those whose total cholesterol levels were more than 224 mg/dL were seven times more likely to have amyloid plaques than those whose total cholesterol was below 173 mg/dl.   The link between elevated LDL-cholesterol, greater than 155 mg/dL and amyloid plaque was even more robust, by a factor of eight, over those whose LDL-C level was below 106 mg/dL.

Omega-3 (Ω-3) fatty acids may also reduce the risk of AD-related dementia, in particular docosahexaenoic acid (DHA) which happens to be a major component of membrane phospholipids in the brain.   Patients with established AD have been found to have lower levels of Ω-3 fatty acids than the general population, and one fish meal per week was associated with a 60% lower risk of developing AD in both the above-mentioned Rotterdam and Chicago studies.   However, as with the vitamin E and C supplements, no studies to date have found an association between fish-oil capsules and a lower risk of developing AD.   You actually have to eat the fish!

The findings regarding vitamin E, cholesterol, and fish, and their association with AD-related dementia certainly support the general recommendation of a Mediterranean diet, with its emphasis on fish, vegetables, fruit, grains, and olive oil, as per the Lancet paper’s conclusions.

But those percentages and ratios – 60% lower risk here, seven or eight times lower risk there – may paint an overly optimistic picture.   We might assume that by adopting all these dietary and other preventive measures, we could add up the lowered risk factors to the point where our risk of becoming demented would be reduced to zero.   Unfortunately, it doesn’t work that way.   As Ecclesiastes said, “…but time and chance happeneth to them all.”   However, in the view of Doc Gumshoe, who is more of an optimist than Ecclesiastes was, the outlook is considerably more rosy than has been generally presented.

A closer look at the trends

Yes, the overall prevalence of Alzheimer’s, not only in the US, but globally, is increasing.   But the main reason for this is that we’re all living longer – in some parts of the world, quite a bit longer.   Several specific trends that are in themselves good news about our health may paradoxically result in increases in the prevalence of AD.   For example, as discussed earlier, vascular risk factors, including hypertension and diabetes, are associated with increasing risks of AD/dementia.   We have seen significant improvements in the treatment of cardiovascular and cerebrovascular disease, and a decline in the incidence of stroke.   As a result, we might expect to see a decline in the incidence of AD.   But there are some contradictions.   There are more persons with subclinical vascular disease being treated with anti-clotting drugs that lessen the likelihood that they will experience a stroke.   And we are also seeing significantly improved survival after stroke.   These persons, many of whom under different clinical circumstances would likely have died of strokes, may now be more likely to progress to AD/dementia.

A careful paper by Walter Rocca and others (Alzheimer’s Dement. 2011 Jan; 7(1): 80–93) examined some of the factors that would be likely to have an impact on the specific incidence and overall prevalence of dementia in the US.   For example, they noted that from 1994 to 2002, in African-Americans over the age of 65 years, the prevalence of hypertension climbed from 73% to 83%, and of diabetes rose 26% to 36%.   These increases, as well as the increase in obesity, may have contributed to an increased risk for cognitive decline and dementia, although this negative impact may not become evident for some time.

But, in the past twenty years, we also have seen an increased level of education among adults in the US over 65.   The proportion of adults age 65 years or older with a high school diploma increased from 53% in 1990 to 72% in 2003, and the proportion with a college degree increased from 11% to 17% during this time period.   Also, the wealth of older adults in the US has risen considerably, from $119,000 in 1989 to $196,000 in 2005 (in constant 2005 dollars).   Both of these factors are thought to contribute to declining levels of disability, including dementia.

Another factor that would be likely to reduce the incidence of dementia is that the percentage of people with elevated levels of cholesterol is declining, and there is a strong association between elevated cholesterol and AD/dementia.   The figures are surprising.   Data from the NHANES report that the overall prevalence of high total cholesterol, defined as greater than 240 mg/dL, has declined from 18.3% in 1999-2000 to 12.4% in 2015-2016.   NHANES is the National Health and Nutrition Examination Survey, and their data are considered to be rock-solid.

A curious finding was that elevated cholesterol was much more common in younger than in older people.   High cholesterol peaked in men between ages 40-59 at 16.5%, but then declined dramatically in those 60 and over, dipping to 6.9%.   (That does not imply that on reaching the sixtieth birthday, cholesterol rates plummeted; more likely that as men reached their senior years they became more conscious of heart health and took steps to mend their previously gluttonous ways.)   Prevalence of elevated cholesterol in white women was higher than in white men, while in black, Hispanic, and Asian women, those prevalences were lower than for men of the same ethnicities.

But in terms of the likelihood of developing Alzheimer’s as well as heart disease, the news that the prevalence of persons with elevated cholesterol levels has declined that much is undeniably good!

What does all this amount to?

No, it doesn’t look as though a magic bullet or a miracle cure is about to appear.   But the likelihood is that a combination of prevention and treatment that both slows the development and ameliorates symptoms, holds out promise of many healthy and undemented years for most of us.

* * * * * * *

And the news continues to trickle out.   On November 6, 2017, just a few days ago, a study supported by the National Institute on Aging, which is part of NIH, was published in Alzheimer’s & Dementia.   This study, based on brain autopsies, found a strong, probably causal relationship between glucose levels in the brain and the severity of amyloid plaques and tangles.   Doc Gumshoe will look at it more closely and report back.   In the meantime, keep those comments coming!   Many thank and best to all, Michael Jorrin (aka Doc Gumshoe).

 

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

81 Comments
Inline Feedbacks
View all comments
msanghadia
Irregular
msanghadia
November 16, 2017 12:15 am

Alzheimer’s is a pretty hard nut to crack. I have not read Dr. Breseden, but, judging from the posts here, he seems to present same old wine (body of knowledge about AD) in a new bottle.

👍 21
SoGiAm
November 16, 2017 6:09 am

In Denmark, exposure to higher lithium levels in drinking water was associated w a lower incidence of dementia https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2649277

Add a Topic
2096
Add a Topic
540
👍 11604
Andy
Member
Andy
November 16, 2017 8:59 am

My grandmother suffered from Alzheimer’s (she died 10 years ago), so it has always been of interest to me an a worry if it is hereditary in any way. 20 years ago it was thought that the use of aluminium pans might have contributed! Thanks to the internet there is a ton of info now available.

I’m in my early 40’s now and keen to reduce my odds and improve my lifestyle. From my research it would appear that diet & lifestyle is a major contributing factor to most age related diseases / conditions. Key is to avoid consuming excessive sugar, processed food and anything that may cause inflammation.

The modern diet is mainly to blame, just walk into a typical supermarket and the vast majority of produce is heavy in sugars or refined grains. If you can stick to the perimeter of the supermarket and avoid the middle aisles you might live OK. Aisles & aisles of soft drinks, biscuits, sugar coated cereals, ready meals & sauces oozing HFCS are not good for us and very addictive.

Modern life is also a factor as we sit all day at school or work and come home and sit in front of the TV or tablet. Stay up too late under artificial light, have too little sleep, breath stale warm air in our centrally heated homes and disinfect everything we touch.

Many health issues are tackled by only treating the symptoms as that is very profitable. If they cured you, then you won’t be back to spend more.

Your gut is very important and you need to look after all the bugs that live in there. Once that system gets out of balance then there will be a huge number knock on effects. Poor uptake of essential nutrients, poor filtration of toxic substances, and poor disposal of waste products. It can get screwed by antibiotics and poor eating habits. It can take a long time to recover too, as we try to live in a sterile environment and don’t eat the right foods to feed the good bacteria in the gut.

Once you lose gut health – you quickly fall into a degrading health spiral.
No drug will cure you if you don’t address the root cause of the problem.

The human body is not required to have 3 meals a day. We used to survive on a diet that varied through the seasons. Sometimes we went without food and sometimes we ate plenty. We are designed to survive these periods without food and store excess as fat in preparation for periods without food. Sugary foods like fruit & berries were only available in the summer, in the winter you had to eat fat & meat…if you could catch it. Now we can eat sugar all year round and consume far too much of it.

We have also lost the ability to quickly turn on our fat burning process and we live in constant Summer mode, building up our fat reserves in preparation for the winter that never comes.

A great resource for expanding you awareness of interesting studies & research in nutrition, health and optimising how your body functions is the podcast The Joe Rogan Experience. I’ve learnt a lot from these episodes. Check out #1037 – Chris Kresser, # 1035 – Paul Stamets, #752 – Mark Sisson, #568 Dr Rhonda Patrick. They have been on a few times so check earlier episodes too.

Cheers Andy

Long – Sleep, Exercise, Coconut Oil, Tumeric, Ketosis, Primal, CBD Oil, Mushrooms, Fermented Food, Lemon, Fat, Butter, Cream, Almonds, Broccoli……..

Short – Pizza, Pasta, Bread, Biscuits, Soda, Sugar, HFCS, CNN

Add a Topic
5198
Add a Topic
1358
Add a Topic
5554
catherine
catherine
November 16, 2017 11:12 am
Reply to  Andy

Andy, Thank you for your very informative post. My list of longs is similar, but also includes blueberries and Vitamin D3. My half-brother and half-sister both had AD, so my interest is also heightened.

👍 204
burghoffer
Irregular
burghoffer
November 16, 2017 9:49 am

Did you look at Biogen’s new drug that has been shown to reduce plaque over time?

👍 15
Jim
Guest
Jim
November 16, 2017 5:41 pm

Big, little, some, or any help can not come fast enough for my wife and I. She has been diagnosed MCI (for at least 4-years) and approaching dementia.
Than you for the info.

SoGiAm
November 16, 2017 9:16 pm

A new study suggests serotonin loss may be a key player in cognitive decline, not just a side effect of #Alzheimers. https://twitter.com/HopkinsMedicine/status/925785720412889090

👍 11604
get_smart
Member
get_smart
November 16, 2017 11:41 pm

I got e-mail from stock $AUPH today that encouraged me to e-mail to find out details on the stock at- https://www.auriniapharma.com/ stated it would clear up all issues on the company.

Add a Topic
5971
Add a Topic
5971
SoGiAm
November 18, 2017 10:14 am

$CWBR What Dr. KSS has been wisely stating, “Researchers must look beyond beta amyloid for Alzheimer’s” Article by Howard M. Fillet, M.D. Founding Executive Director and Chief Scientific Officer of the Alzheimer’s Drug Discovery Foundation in Statnews.com Best, Dara https://www.statnews.com/2017/11/17/beta-amyloid-alzheimers-drugs/
Comment Link: https://www.stockgumshoe.com/2017/11/notes-from-torrey-hills-capital-emerging-growth-conference-13-15-november-2017-san-diego-ca/comment-page-1/#comment-4960428 Best2ALL!

Add a Topic
3932
👍 11604
gunstar50
Irregular
November 18, 2017 8:01 pm
Reply to  SoGiAm

Ben as always, thank you. You give so much to this site in so many areas. I for one appreciate you greatly.

👍 116
gaevans
Member
gaevans
November 18, 2017 10:47 am

Good Article, I just finished Dr. Dale Bredesen’s, new Book; “The End of Alzheimer’s”. According to Dr. Bredesen there at least 36 factors that contribute to the development of Alzheimer’s. Check out this very interesting book, or his website, http://www.drbredesen.com/mpicognition for an overview.
Thanks

👍 2
Marc
Irregular
Marc
November 18, 2017 8:21 pm

I watched a program about a community in the US ten years ago where all of the people lived, partied and played together throughout the remainder of their lives. A young doctor was hired to look after the community and she kept track of all of their health needs. Many lived into their 90’s and donated their brains for research. Many of the healthy ones were found to have amyloid plaque in their brains but had no dementia. My understanding is that all people will get some form of dementia and Alzheimer’s is just one type. David Suzuki has done a show on Alzheimer’s as it affected his mother. He discovered two cures. For some reason they are not spoken about in any community I can see. One cure was to drill two holes and push rods into these holes while the patient was still awake. The rods were twisted and turned as they were pushed in further (a set distant I am sure) until all of a sudden the patient had very vivid memories rush back into their mind. Very few surgeries of this kind had been done at that point, but there was reportedly lasting effects. From what I am told about Lewy’s, it appears in people more often that have been exposed to a variety of chemicals. Firefighters are being diagnosed at an alarming rate with this disease.

Ed Gossack
Guest
Ed Gossack
November 20, 2017 9:58 am

Michael Jorrin – This was posted on the ihub message board this morning. This is too lengthy for your comment section but it could possibly give a quick synopsis of Anavex’s A2-73 progression to date should you be interested. Re:Post #131122

Investor2014 Monday, 11/20/17 07:44:47 AM
Re: None
Post #
131122
of 131144 Go
Has Anavex progressed too slowly and not kept shareholder abreast with developments?

A review of the evidence and timeline would suggest that Anavex have very carefully planned and executed on a path leading to a modern pivotal CNS study and “the first of its kind to broaden the scope of drug development in Alzheimer’s disease and other central nervous system diseases,” said George Perry, PhD, Dean of the College of Sciences at The University of Texas at San Antonio and editor-in-chief of the Journal of Alzheimer’s Disease.

I conclude that the time it is taking Anavex to launch the next confirmatory P2/3 trial in AD, is entirely determined by the study design timelines and the thorough pre-planned data analysis needed to minimise the risk and cost of failure.

Please take your time to carefully digest the progression below and tell me where the company could have done better on the timing and release of information.

I would also suggest taking a look at the timelines and cost of recent failed Alzheimer’s studies to see how they compare.

December 16, 2014: Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

http://www.anavex.com/anavex-begins-enrollment-of-alzheimers-patients-in-phase-2a-clinical-trial-of-anavex-2-73-and-anavex-plus/

July 22, 2015: Anavex Presents Positive Initial Phase 2a Study Data with ANAVEX 2-73 showing Early Evidence of Improving Cognition in Patients with Alzheimer’s Disease at AAIC 2015

http://www.anavex.com/anavex-presents-positive-initial-phase-2a-study-data-with-anavex-2-73-showing-early-evidence-of-improving-cognition-in-patients-with-alzheimers-disease-at-aaic-2015/

“Subsequent to the positive initial feedback, we are applying to expand the extension period from 26 weeks to 52 weeks at the request of the participants.”

September 28, 2015: Anavex Completes Patient Enrollment for Phase 2a Alzheimer’s Trial Ahead of Schedule

http://www.anavex.com/anavex-completes-patient-enrollment-for-phase-2a-alzheimers-trial-ahead-of-schedule/

Comment: Add 52 weeks for the last patient enrolled to complete the study gets us to end September 2016!

November 9, 2015: Anavex Announces Positive Primary and Secondary Endpoints were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer’s Disease?

http://www.anavex.com/anavex-announces-positive-primary-and-secondary-endpoints-were-achieved-in-a-phase-2a-clinical-trial-of-anavex-2-73-in-alzheimers-disease%e2%80%8e/

“In the interim analysis of the first 14 patients at week 12, the PART B portion of the study demonstrated a positive trend towards improvement over 12 weeks of ANAVEX 2-73 treatment on the secondary functional outcome measure, the Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory (ADCS-ADL) by +3.21 points.”

Comment: Notice that at this point the readout is based on data for the first 14 patients at week 12 of the original 26 weeks Part B study.

November 11, 2015: Anavex Confirms Data for Phase 2a Alzheimer’s Trial for ANAVEX 2-73

http://www.anavex.com/anavex-confirms-data-for-phase-2a-alzheimers-trial-for-anavex-2-73/

Comment: In the wake of attacks on the data as meaningless and drop in share price, Anavex chooses to confirm that the science and data presented 9th November really is true

November 18, 2015: Anavex Announces Preparation of Regulatory Filings based on Guidance From the FDA

http://www.anavex.com/anavex-announces-preparation-of-regulatory-filings-based-on-guidance-from-the-fda/

Comment: The Phase 2a Part B study as extended to 52 weeks is still at this point ongoing with the last enrolled patient, according to my maths, expected to complete the study end September 2016. One could say this is very timely preparation looking ahead to start the detailed pre-planned data analysis. We know that the FDA are themselves using the Ariana KEM technology and have most likely guided Anavex to do the same perhaps in the presence of Dr. Fadiran.

No Post-Hoc mining here!

January 11, 2016: Anavex Announces Positive Dose-Response Data for ANAVEX 2-73 in Alzheimer’s Disease Patients

http://www.anavex.com/anavex-announces-positive-dose-response-data-for-anavex-2-73-in-alzheimers-disease-patients/

Comment: The Dose-Response data is based on the 5 weeks Part A data. The first patient was enrolled in December 2014 and the last patient would have completed Part A around end September 2015 coinciding with beginning the enrolment for the 52 weeks extension study completed.

March 10, 2016: Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference

http://www.anavex.com/anavex-announces-two-year-clinical-extension-study-of-anavex-2-73-and-presents-phase-2a-dose-response-analysis-at-aat-conference/

Comment: This is the NEW 104 weeks extension study A2-73– 003 on top of the Part A 5 weeks + Part B 52 weeks study (replacing the original 26 weeks Part B study).

July 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016

http://www.anavex.com/anavex-presents-31-week-safety-data-from-phase-2a-study-of-anavex-2-73-in-alzheimers-patients-at-aaic-2016/

July 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016

http://www.anavex.com/anavex-presents-31-week-efficacy-data-from-phase-2a-study-of-anavex-2-73-in-alzheimers-patients-at-aaic-2016/

July 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients Presented at AAIC 2016

Comment: Anavex again gets hammered by the market’s interpretation of the data and share price drops. Dr. Norman Relkin, MD, PhD, confirms how to interpret the data.

October 5, 2016: Anavex Life Sciences and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs

http://www.anavex.com/anavex-life-sciences-and-ariana-pharma-collaborate-to-accelerate-timelines-and-improve-efficiency-of-alzheimers-and-parkinsons-clinical-development-programs/

“Anavex’s 32-patient Alzheimer’s study utilizing KEM® will enable systematic analysis of more data on each patient in the disease group, on par with similar studies of significantly larger size, while providing greater cost and time efficiency.”

“The ongoing Phase 2a Alzheimer’s clinical trial was specifically designed to learn as much as possible about ANAVEX 2-73 in order to optimize trial parameters for future pivotal trials and potentially reduce the risk of failure in a later, larger Phase 2/3 study and in a planned Parkinson’s Phase 2 study. We believe that the collaboration with Ariana Pharma will potentially accelerate the development process,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.”

Comment: The last patient would have completed the 52 weeks Part B extension around end September 2016, meaning that the Ariana collaboration announcement is coinciding with having all the required data available. Little doubt in my mind that the use of Ariana KEM Analysis was planned well in advance as per the November 18, 2015 PR when “Anavex Announces Preparation of Regulatory Filings based on Guidance From the FDA”

From the 2nd quote above, I think we may also infer that the AD and PD trials will share the relevant parts of inclusions/exclusion criteria and elements of trial design, especially when the PD P2 trial is followed by a pivotal PD trial. At this point the Rett P2 grant etc. was not yet known, so not sure to what extent the Rett trial will share criteria and design with the upcoming PD and AD trials – time will tell.

November 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease

http://www.anavex.com/anavex-life-sciences-announces-data-on-41-week-treatment-of-anavex-2-73-for-patients-with-alzheimers-disease/

December 8, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients

http://www.anavex.com/anavex-life-sciences-announces-12-month-data-of-anavex-2-73-in-a-phase-2a-study-in-mild-to-moderate-alzheimers-disease-patients/

“Despite non-optimized dosing of ANAVEX 2-73 throughout the 12-month study, continued significant improvements from baseline of cognitive, functional and behavioral scores in a group of patients were observed, respectively. This data will be analyzed using refined mathematical modeling methods in conjunction with the detailed pharmacokinetic (PK) information.”

Comment: Given enrolment timelines, the 52 weeks of data for all patients is finally available and KEM Analysis can start.

October 12, 2017: Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease Patients; Conference call today at 8:30am ET

http://www.anavex.com/anavex-life-sciences-reports-pk-pd-data-phase-2a-trial-anavex2-73-mild-moderate-alzheimers-disease-patients-conference-call-today-830am-et/

“I welcome such a thorough analysis of data before moving into a Phase 2/3. The intriguing ANAVEX2-73 data shown thus far exemplifies a precision medicine approach, to my knowledge, the first of its kind to broaden the scope of drug development in Alzheimer’s disease and other central nervous system diseases,” said George Perry, PhD, Dean of the College of Sciences at The University of Texas at San Antonio and editor-in-chief of the Journal of Alzheimer’s Disease.

“The Company is identifying the best responders to ANAVEX2-73 by using Ariana Pharma’s KEM® advanced Artificial Intelligence technology. This cutting edge trial analysis will be used to more effectively design the upcoming Phase 2/3 clinical study, raising the odds of late stage trial success.”

Comment: I conclude that the Ariana KEM Analysis has taken less than 11 months to conclude. 52 weeks data from all 25 patients was finally available December 2016 and KEM Analysis was presented November 2017. During this time Anavex is quiet regarding the A2-73 study in AD, but announces several pre-clinical and clinical milestones in other indications and for A3-71.

Is less than 11 months a long time to conduct a multi-factor Population PK/PD study?

Considering the cost implication of a failed confirmatory trial, it makes huge sense to spend sufficient time to secure the veracity of data in a Population PK/PD study in the case of Anavex using modern KEM Analysis. Not least because of the ethical implications regarding the patients and before spending the money and effort on a pivotal trial. The paper below gives some insights to the importance.


Project Management Aspects

Reviews of filings in the United States and Europe made between 1991 and 2001 showed that the average success rate for all candidate drugs in all therapeutic areas was ~11%,41 and that the success rate was lower during preclinical development. With the cost of conducting clinical trials increasing with each stage in drug development, failure at late stages of development is problematic. The costs associated with drug development are staggeringly high. In 2010, the cost of developing a new drug was estimated to be ~$1.2 billion (costs vary depending on the therapeutic indication).42 Part of the problem is difficulty in making informed decisions at critical junctures during the drug development process.
In 1997, Sheiner43 introduced the concept of “Learn and Confirm” as a means to improve decision making by using information more effectively. Sheiner outlined a drug development process that involved two cycles of learning and confirming (Table 3). During the learning phases of each cycle, studies should be designed to answer broader questions, and require more elaborate evaluations to answer; in contrast, during the confirming phases, questions are typically of the “yes/no” variety and can be answered using traditional statistical approaches. Sheiner advocated the use of modeling as a means of addressing the learning questions and of improving the information from confirming questions by providing a basis for explaining the variations in the data and increasing the power to detect meaningful clinical results.44”

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606044/

November 4, 2017: Anavex Life Sciences-New Clinical Data on Alzheimer’s Disease

http://www.anavex.com/new-clinical-data-alzheimers-disease/

“Data presented include new results from the Phase 1 study (ANAVEX®2-73-001), the Phase 2a study (ANAVEX®2-73-002), and data from the first year of the Phase 2a long-term extension study (ANAVEX®2-73-003).
At 109 weeks and halfway into the long-term extension Phase 2a study ANAVEX®2-73-003, data from the cohort of patients with the highest ANAVEX2-73 concentrations point towards the continued ability of the medication to stop the decline in the exploratory secondary endpoints cognition (MMSE) and function (ADCS-ADL). At 57 weeks, this cohort had demonstrated improvement of the measures MMSE and ADCS-ADL compared to baseline. For the primary endpoint, ANAVEX2-73 demonstrated continued favorable safety and tolerability through 109 weeks.”

Comment: Note that we are going all the way back to Single Ascending Dose (SAD) Phase 1 clinical study in healthy volunteers conducted in Germany. Another sign that we are looking at a well-planned route navigated with precision over nearly 3 years to deliver a modern CNS study and “the first of its kind to broaden the scope of drug development in Alzheimer’s disease and other central nervous system diseases,” said George Perry, PhD, Dean of the College of Sciences at The University of Texas at San Antonio and editor-in-chief of the Journal of Alzheimer’s Disease.

Add a Topic
2866
Add a Topic
2866
Add a Topic
2866
Kris
Kris
November 20, 2017 11:00 pm

There is no miracle pill to cure anything including AD. But it would be so convenient if one existed. Diet and lifestyle changes are needed. Do a search on Amazon Books for the works of dr Bruce Fife. Incredible research he’s done on effect of Ketogenic diet and coconut oil.

Add a Topic
5198
Add a Topic
34
Add a Topic
5198
Alex Green (alexgreen)
Guest
November 28, 2017 12:27 pm
Reply to  Kris

Noticed below I said “cure” instead of treatment. You are right there is not cure, nerveless still a very important focus in the medical space right now.

Alex Green (alexgreen)
Guest
November 28, 2017 12:20 pm

We have 100 reasons to like (GILD) right now, which isn’t a direct relation to the article above but if your looking to get into the space for curing Alzheimers, better believe GILD is too. Recently acquiring KITE Pharma for its CAR-T cancer treatment its no time before they’re providing treatment for this disease as well.

Add a Topic
5805
Add a Topic
3397
Travis Johnson, Stock Gumshoe
November 28, 2017 12:33 pm

Not sure why you’d combine “Gilead” and “Alzheimer’s” in a sentence. I have never seen any indication that Gilead is doing anything in the neurological space, and the word “Alzheimers'” doesn’t even appear on their website.

👍 21650
Alex Green (alexgreen)
Guest
November 28, 2017 1:51 pm

As I mentioned in my comment there is no direct relation to the article. However, one of GILD main competitors is a leader in AD treatment. Can you say with certainty that its not something they’ve considered adding to there list of subsidiaries through an acquisition? Who knows. Sure that is speculative, but it doesn’t take away from the fact that GILD is a great investment right now.

owo123
January 9, 2018 4:31 pm

Any reason why ACAD was not mentioned here, considering the fact that they are in Phase 3 for AD with a drug already approved for Parkisons?

👍 31
👍 652

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info  
32
0
Would love your thoughts, please comment.x
()
x